Wall Street analysts expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will post ($0.83) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.70) and the lowest estimate coming in at ($0.97). Voyager Therapeutics reported earnings of ($0.80) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 3.7%. The business is expected to report its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.92) per share for the current year, with EPS estimates ranging from ($3.92) to ($1.30). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.86) to ($1.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($1.46). Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. The company had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $3.00 million.
In related news, major shareholder Neurocrine Biosciences Inc purchased 4,179,728 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $11.96 per share, for a total transaction of $49,989,546.88. Following the acquisition, the insider now owns 4,179,728 shares in the company, valued at $49,989,546.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.60% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG3 Management LLC acquired a new stake in Voyager Therapeutics in the 1st quarter valued at $57,000. BNP Paribas Arbitrage SA increased its holdings in Voyager Therapeutics by 74,766.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after purchasing an additional 4,486 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Voyager Therapeutics by 1,800.0% in the 1st quarter. Macquarie Group Ltd. now owns 5,700 shares of the company’s stock valued at $109,000 after purchasing an additional 5,400 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in Voyager Therapeutics by 449.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after purchasing an additional 7,401 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Voyager Therapeutics by 211.0% in the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after purchasing an additional 7,217 shares in the last quarter. Hedge funds and other institutional investors own 74.46% of the company’s stock.
Shares of VYGR stock traded up $1.27 on Friday, reaching $24.12. 268,094 shares of the stock were exchanged, compared to its average volume of 503,092. The company has a market cap of $888.39 million, a price-to-earnings ratio of -8.77 and a beta of 2.82. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $25.74.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Read More: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.